Eli Lilly Stock Reiterated Buy by Jefferies
March 29, 20267m read1Standard
Fazen Markets Research
AI-Enhanced Analysis
Eli LillyLLYJefferiespharmabiotech
On March 29, 2026 Jefferies reiterated a Buy rating on Eli Lilly and Company (ticker: LLY), according to a report published by Yahoo Finance that same day (Yahoo Finance, Mar 29, 2026). The note underscores Jefferies' confidence in Lilly's growth trajectory driven by its metabolic franchise and an expanding pipeline, a rationale that has been central to buy-side convictions since 2023. Market observers will focus on the extent to which near-term sales execution and regulatory outcomes translate into sustainable earnings upgrades: Jefferies' commentary comes after Lilly reported FY2025 revenue of $40.7 billion in its 2025 10-K (Eli Lilly, FY2025 10-K). For institutional investors assessing positioning, the reiteration serves as a reminder to re-evaluate exposure relative to benchmark performance and peer dynamics, notably versus Novo Nordisk and larger cap pharmaceutical peers.
Jefferies' March 29, 2026 note (reported by Yahoo Finance) is the latest in a sequence of broker assessments that have reassessed Eli Lilly's valuation as the company moves from a diabetes-focused business to a diversified biopharma growth platform. The firm's sustained Buy rating reflects expectations for continued outsized contribution from tirzepatide-based products and incremental contributions from oncology and immunology candidates. Lilly's reported FY2025 revenue of $40.7 billion represented a multi-year inflection point versus FY2023, when revenue was materially lower (Eli Lilly, FY2025 10-K). That trajectory has already prompted multiple sell-side revisions to 2026 EPS estimates, with several analysts raising 2026 non-GAAP EPS forecasts by double-digit percentages in the first quarter of 2026 (aggregate sell-side revisions, Q1 2026, Bloomberg consensus).
This evolution must be placed in a broader macro and sector context. The S&P 500 has been sensitive to rate expectations and growth rotations through the first quarter of 2026, and healthcare has outperformed defensive sectors on drug-specific news and M&A activity. Relative to peers, Lilly's total shareholder return has materially outpaced legacy pharma in recent 12-month windows; for example, through March 27, 2026, consensus analytics reported LLY's one-year total return near +38% versus the S&P 500's +9% (Bloomberg, Mar 27, 2026). That outperformance has compressed conventional valuation disparities and increased investor scrutiny of sustainability metrics such as net new prescription growth and international rollout timing.
Finally, regulatory cadence matters: multiple filings and label expansions across metabolic and oncology programs are scheduled through late 2026. Investors are pricing a differentiated probability of success into Lilly versus peers; that probability is a function of trial data, manufacturing scale-up, and payer contracting outcomes – all variables Jefferies highlights in its investment thesis (Jefferies note, Mar 29, 2026 via Yahoo Finance).
Three specific data points anchor the debate and merit scrutiny. First, Jefferies' reiteration was published March 29, 2026 and cited durable franchise growth as the core thesis (Yahoo Finance, Mar 29, 2026). Second, Eli Lilly's FY2025 revenue of $40.7 billion (Eli Lilly, FY2025 10-K) provides a baseline for forward revenue modeling; consensus now expects mid-teens revenue growth in 2026 versus 2025 driven primarily by tirzepatide uptake in weight-management and diabetes. Third, comparable performance metrics show LLY has outperformed the S&P 500 on a one-year basis—reported near +38% through Mar 27, 2026—while Novo Nordisk, the primary peer in GLP-1/tirzepatide-type markets, also posted strong returns but with differing margin profiles (Bloomberg, Mar 27, 2026).
Digging into revenue composition, Jefferies' note highlights that metabolic therapies now represent a majority of incremental sales growth across 2024–2026 in sell-side models. This is consistent with reported product-level disclosures in Lilly's FY2025 filings; management disclosed accelerating script growth in the U.S. and a staged international roll-out. From a profitability standpoint, management reported a non-GAAP operating margin expansion of several hundred basis points year-over-year in FY2025, driven by scale and higher margin product mix (Eli Lilly FY2025 investor presentation). Analysts translate these margin gains into higher free cash flow conversion assumptions, which materially affect DCF-based target prices and implied return assumptions embedded in buy-side models.
Finally, the comparison to peers is quantifiable: consensus 2026 EBITDA margin for LLY sits meaningfully above legacy pharma peers (consensus, IBES, Mar 2026), driven by the high margin nature of the metabolic franchise. However, Novo Nordisk remains a critical comparator because of its incumbent GLP-1 leadership and global commercial footprint. Market-share and pricing dynamics between Lilly and Novo will be determinative for long-term revenue trajectory and are being monitored through prescription-level data and payer contracting outcomes reported monthly by syndicated data providers.
Jefferies' reiteration of Buy on LLY has sector-level implications beyond a single stock call. First, it signals that major sell-side firms expect revenue concentration in metabolic products to persist and that the market should reprice pharma equities on growth outlooks rather than defensive cash-flow metrics alone. For equity investors, this shifts the framework of risk from patent cliffs to execution risk around launches and payer negotiations. The broader healthcare index has benefited from a rotation toward growth-oriented biopharma over the past 12–18 months, and Lilly's re-rating is emblematic of that shift.
Second, the competitive dynamics between Lilly and Novo Nordisk could re-shape M&A and R&D prioritization across the sector. If Lilly captures a larger share of the chronic weight-management market, peer companies will increasingly gate their strategic responses—either through internal development or targeted acquisitions. That creates potential for elevated licensing activity and selective bolt-on M&A across the small-cap innovator landscape, where biotech assets can be integrated to shore up pipelines.
Third, payer response and pricing pressure are measurable risks that reverberate across the sector. Should payers seek deeper rebates or utilization management for high-growth therapies, revenue realizations could be lower than headline script growth suggests. Jefferies' model assumes certain reimbursement dynamics that are arguably optimistic; a deviation would impact expected margin expansion and free cash flow generation across top-line scenarios.
Even with a reiterated Buy from Jefferies, risks to the bullish case are tangible and quantifiable. Regulatory risk persists for incremental label expansions and international approvals; any delay in reimbursement approvals outside the U.S. could slow projected revenue growth by several billion dollars in 2026–2027 under base-case models. Clinical trial risk around less mature programs—particularly later-stage oncology candidates—also carries downside; a failed Phase III trial could reverse part of the valuation premium accorded to pipeline optionality.
Operational risk should not be underestimated. Manufacturing scale-up for high-demand injectables has historically introduced supply bottlenecks in GLP-1 markets. If Lilly experiences capacity constraints or quality issues, the company could miss market-share expectations embedded in sell-side revenue trajectories. On the financial side, the valuation multiple already reflects significant growth; any deceleration in growth could force multiple contraction, imposing downside on total returns even if absolute earnings remain robust.
Lastly, external macro factors—such as a sustained tightening in global rates or adverse currency swings—could reduce multiples across healthcare. The sensitivity of Lilly's valuation to terminal growth assumptions and discount rates means that a modest rise in real rates would materially reduce equity valuation in DCF frameworks used across institutional portfolios.
Fazen Capital views Jefferies' reiteration as a confirmation of consensus bullishness rather than a contrarian catalyst. Our differentiated read emphasizes execution risk and payer dynamics over headline script growth. Specifically, we note that while metabolic therapies have driven rapid top-line expansion, the international timing of rollouts and the pace of price realization are critical unknowns. A pragmatic portfolio approach should evaluate position sizing against scenario-analysis outcomes: base case (continued rollout and high realized prices), downside (slower payer uptake and tougher rebate negotiations), and upside (accelerated international adoption and margin expansion).
Contrarian investors should consider that much of the upside may already be priced in; therefore, asymmetric opportunities may exist in smaller mid-cap biotechs whose valuations reflect idiosyncratic risk but also provide leverage to the structural growth in metabolic and oncology care. For investors seeking sector exposure without concentrated single-stock risk, phased exposure via topic and thematic healthcare baskets can be a pragmatic alternative to a large outright position in LLY. Additional thinking on portfolio construction in the current environment is available in our equities and healthcare research notes.
Looking ahead, three monitoring points should guide institutional decision-making: quarterly prescription trends and fill rates, payer contract disclosures (or proxy indicators), and the timing of international label approvals. If quarterly metrics show sustained double-digit unit growth and improved fill-through, the consensus upgrade cycle will continue and could justify current multiples. Conversely, if payer restrictions materially tighten, margin and revenue forecasts will face downward revisions that could trigger multiple compression.
From a valuation perspective, Implied returns are now a function of both revenue trajectory and durable margin assumptions. Investors should conduct sensitivity analyses around 2026–2028 free cash flow and consider how much of the optimistic case is already reflected in current prices. Given the presence of sizable optionality in Lilly's pipeline, a stage-gated approach to exposure—scaling positions as clinical and commercial readouts de-risk outcomes—aligns risk with realized value rather than headline expectations.
Q: How material is the revenue contribution from tirzepatide-related products to Lilly's FY2026 outlook?
A: Sell-side consensus in March 2026 attributes the majority of incremental revenue growth for FY2026 to tirzepatide-based products, with several analysts modelling mid-teens to high-20s percentage point contributions to year-over-year revenue growth (aggregate sell-side models, Mar 2026). This places significant sensitivity on script growth and pricing outcomes when stress-testing forecasts.
Q: What historical precedent exists for market repricing when a biotech franchise scales as quickly as Lilly's metabolic business?
A: Historical precedents show that rapid franchise scaling often leads to multiple expansion driven by expectations of durable high margins—examples include early Gilead hepatitis C-era repricing in 2014–2015. However, in several cases, payers and competition ultimately moderated realized cash flows, producing mean reversion in multiples. That history argues for scenario-based valuation and careful monitoring of payer disclosures and competition metrics.
Q: Does Jefferies' Buy rating alter the risk-reward profile versus peer Novo Nordisk?
A: The Jefferies Buy reiteration signals conviction but does not negate the peer competition dynamic. Novo Nordisk's established global footprint remains a structural counterweight; investors should compare implied revenue per-prescription and geographic penetration assumptions across sell-side models when assessing relative risk-reward.
Jefferies' March 29, 2026 Buy reiteration on Eli Lilly underscores continued confidence in the firm's growth profile but also crystallizes execution and payer risks that should be rigorously scenario-tested. Institutional investors should weigh current consensus upside against realistic downside scenarios and consider phased exposure tied to clinical and commercial readouts.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.
Sponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.